Our case demonstrates the efficacy of ven/dex in an aggressive and refractory pPCL patient with t(11;14) and TP53 mutation and, in this case, IgM-subtype....He progressed on proteasome inhibitors, immunomodulating agents, and other chemotherapy medications but later achieved very good partial response (VGPR) to venetoclax and dexamethasone...